Cadrenal Therapeutics, Inc. (CVKD) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing tecarfarin, a novel oral vitamin K antagonist (VKA) designed as a safer alternative to warfarin for patients with specific cardiovascular conditions, including those with left ventricular assist devices (LVADs) and end-stage kidney disease (ESKD). The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,845,380) | $(1,663,288) |
| Loss Per Share (Basic & Diluted) | $(2.09) | $(1.56) |
| Cash and Cash Equivalents (End of Period) | $7,336,072 | $6,566,418 |
| Net Cash Used in Operating Activities | $(4,648,755) | $(1,836,380) |
| Net Cash Provided by Financing Activities | $1,970,136 | $298 |
| Total Assets | $7,953,262 | $10,123,533 |
| Accumulated Deficit | $(29,568,163) | $(16,734,703) |
Note: The filing does not provide revenue or gross margin data as the company has no commercial product sales. Operating expenses are the primary driver of the loss.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by $2.17 million (124%) to $3.93 million.
- General and Administrative (G&A): Increased by $1.13 million (100%) to $2.25 million, driven by public company costs, stock-based compensation, and personnel expenses.
- Research and Development (R&D): Increased by $1.04 million (165%) to $1.67 million, attributed to chemistry, manufacturing, and controls (CMC) costs, clinical trial preparation, and severance for the former Chief Medical Officer.
- Financing Activity: The company raised approximately $2.06 million in gross proceeds during Q1 2025 through its At-The-Market (ATM) facility, compared to negligible financing activity in Q1 2024.
- Liquidity: Cash balances decreased by approximately $2.68 million during the quarter due to operating burn, partially offset by financing proceeds.
Outlook, Risks, and Management Commentary
- Liquidity Position: As of May 8, 2025, the company held approximately $6.9 million in cash (including subsequent ATM sales). Management expects this to fund operations for at least the next twelve months. However, additional funding is required to conduct late-stage clinical trials, specifically a Phase 3 trial for tecarfarin.
- Capital Strategy: Management intends to raise additional funds through partnering, equity sales, or debt financing. There is no assurance that such funding will be available on acceptable terms.
- Risks: The company faces standard biotech risks, including dependency on the clinical success of tecarfarin, regulatory approval uncertainty, and the need for substantial additional financing. Failure to secure funding could force the company to delay or cease operations.
- Subsequent Events: Between April 1 and May 7, 2025, the company sold an additional 56,943 shares via its ATM facility for net proceeds of approximately $876,000.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the ~$6.9 million cash balance against the projected costs of the upcoming Phase 3 clinical trial.
- ATM Facility Usage: Monitor the frequency and pricing of shares sold through the ATM facility, as this indicates ongoing dilution and capital needs.
- Clinical Milestones: Confirm the timeline and budget for the initiation of the Phase 3 trial for tecarfarin in LVAD and ESKD+AFib populations.
- Expense Management: Review the sustainability of the increased G&A and R&D burn rate, particularly the impact of the former CMO's severance and new hires.
- Dilution Impact: Assess the impact of outstanding warrants (615,940 shares) and options (436,334 shares) on future share count and per-share value.